Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Therapeutics, Inc. (MGX)
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced a publication in Nature Structural & Molecular Biology highlighting the discovery and detailed characterization of MG119-28, a compact CRISPR nuclease with superior editing efficiency relative to previously identified compact nucleases. The publication, titled “Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency” highlights the potential of MG119-28 (formally named Al3Cas12f) to overcome low editing efficiency in mammalian systems of previously identified compact nucleases from the Cas12f class. The publication demonstrates that the enhanced editing performance is due to superior structural stability of the protein and inherently more stable guide RNA w
Show less
Read more
Impact Snapshot
Event Time:
MGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGX alerts
High impacting Metagenomi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MGX
News
- Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire
- Metagenomi (MGX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MGX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
- Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsGlobeNewswire
- Metagenomi Therapeutics, Inc. (MGX) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]Seeking Alpha
MGX
Earnings
- 5/13/25 - Miss
MGX
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- MGX's page on the SEC website